Devita, Hellman, and Rosenberg's Cancer

LWBK1006-31 LWW-Govindan-Review December 12, 2011 19:43

442 DeVita, Hellman, and Rosenberg’s CANCER: Principles and Practice of Oncology Review

Question 31.23. Dexamethasone has replaced prednisone in ALL induction therapy

because of improved penetration in which tissue?

A. Testes

B. Spleen

C. Bone marrow

D. Brain

Question 31.24. Maintenance therapy for ALL with daily 6-mercaptopurine, weekly

methotrexate, and monthly vincristine and prednisone should be con-

tinued for how long?

A. 6 months

B. 12 months

C. 24 to 36 months

D. Until relapse

Question 31.25. Which of the following targeted agents have been shown to be beneficial

in adult ALL?

A. Imatinib

B. Alemtuzumab

C. Gemtuzumab ozogamicin

D. Sunitinib

Question 31.26. For which of the following patients would you consider myeloablative

stem cell transplantation in CR1?

A. A 30-year-old woman with inv(16) AML-M4 with eosinophilia

B. A 50-year-old man with complex cytogenetics AML-M1

C. A 65-year-old man with complex cytogenetics AML-M1

D. A 50-year-old woman witht(15;17) AML-M3

Question 31.27. All of the following statements are true regarding the nucleophosmin 1

(NPM1) mutation in AML EXCEPT:

A. NPM1 gene encodes a protein that functions as chaperone between

the nucleus and cytoplasm.

B. NPM1 mutations are found only in patients with AML with normal

karyotype.

C. NPM1 mutations in the absence of FLT3-ITD have good prognosis.

D. Aberrant cytoplasmic localization of NPM1 is associated with muta-

tion in the gene.